Ernexa
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1035 Cambridge St 18A, Cambridge, Massac...Phone Number
(617) 798-6700Website
www.ernexatx.comRevenue
-Stock Symbol
ERNAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Ernexa
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. ERNA-101 is the Companys lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The Companys initial focus is to develop ERNA-101 for the treatment of ovarian cancer.Explore more
Ernexa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ernexa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ernexa recently announced quarterly report
Check out if Ernexa is spiking on competitors!
Product Launch: Get notified when Ernexa launches new products
Funding: Get notified immidiatlly once Ernexa has new funding data
Check if Ernexa has recently received funding, and reach out quickly before it becomes old news!
Ernexa, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Ernexa
Click to see if Ernexa had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Ernexa as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Ernexa is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ernexa is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ernexa.
Ernexa financials insights
Gather financial insights about Ernexa, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$15.1M
Private Equity
$40.6M
2016
Multiple Rounds
$41.6M
2020
Debt
$150K
2021
Unspecified
$20M
Stock Offering
$40.7M
2026
Stock/Share Issuance
$10.5M
Ernexa Tech Stack
A closer look at the technologies used by Ernexa
See more technologies
Most Recent Scoops
Funding
Funding
Earnings
Earnings, Finance
Project
Ernexa has approved an increase to its authorized shares of common stock from 100 million to 150 million shares.
Financial Planning, Corporate Strategy, Finance, Financial Strategy
Executive Move
Executive Moves, Video
Partnership
Project
Partnership, Product Management, Intellectual Property, Bioengineering, Medical Research, Healthcare Technology
Ernexa News & Media
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncologyErnexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology companyErnexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ernexa
Sign Up For FreeTo access detailed company insights
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexas core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexas allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatm... Read More
